News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
byJairia Dela Cruz
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.








